D. Narayanan and O. K. Weinberg, How I investigate acute myeloid leukemia, Int J Lab Hematol, 2019.

. Hematopathology, , 2019.

T. Murphy and K. Yee, Cytarabine and daunorubicin for the treatment of acute myeloid leukemia, Expert Opin Pharmacother, vol.18, issue.16, pp.1765-80, 2017.

S. M. Luger, How can one optimize induction therapy in AML?, Best Pract Res Clin Haematol, vol.30, issue.4, pp.301-306, 2017.

C. Saygin and H. E. Carraway, Emerging therapies for acute myeloid leukemia, J Hematol OncolJ Hematol Oncol, vol.10, issue.1, p.93, 201718.

, Emerging drug profile: CPX-351 (vyxeos) in AML. -PubMed -NCBI, 2019.

, VYXEOS 44 mg/100 mg poudre pour solution à diluer pour perfusion -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.

H. Autorité-de-santé, , 2020.

, Advances in treatment formulations for acute myeloid leukemia. -PubMed -NCBI, 2019.

E. J. Feldman, J. E. Kolitz, J. M. Trang, B. D. Liboiron, C. E. Swenson et al., Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia, Leuk Res, vol.36, issue.10, pp.1283-1292, 2012.

J. E. Lancet, G. L. Uy, J. E. Cortes, L. F. Newell, T. L. Lin et al., CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.26, pp.2684-92, 201810.

J. E. Godwin and S. E. Smith, Acute myeloid leukemia in the older patient, Crit Rev Oncol Hematol, vol.48, pp.17-26, 2003.

A. Burnett, M. Wetzler, and B. Löwenberg, Therapeutic advances in acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.5, pp.487-94, 2011.

, Laboratoire d'Hématologie Cellulaire du CHU d'Angers, 2019.

H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Büchner et al., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 2010.

, Résumé des caractéristiques du produit -CYTARABINE ACCORD 100 mg/ml, solution injectable ou pour perfusion -Base de données publique des médicaments, 2019.

. Vidal--cytarabine, , 2019.

. Cytarabine, Wikipédia [Internet, 2020.

N. Navaratnam and R. Sarwar, An overview of cytidine deaminases, Int J Hematol, vol.83, issue.3, pp.195-200, 2006.

C. D. Steuart and P. J. Burke, Cytidine deaminase and the development of resistance to arabinosyl cytosine, Nature New Biol, vol.233, issue.38, pp.109-119, 1971.

R. L. Momparler, N. Onetto, L. F. Momparler, M. Gyger, J. M. Leclerc et al., Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy, Semin Oncol, vol.12, issue.2, pp.31-34, 1985.

, CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine, 2019.

. Vidal--anthracyclines, intercalants : Classification Vidal, 2019.

S. Bertoli and C. Récher, Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes. Rev Francoph Lab, pp.65-73, 2015.

C. Gardin, S. Chevret, C. Pautas, P. Turlure, E. Raffoux et al., Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.3, pp.321-328, 2013.

, A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, 2019.

S. C. Semple, A. Chonn, and P. R. Cullis, Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry (Mosc), vol.35, pp.2521-2526, 1996.

, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. -PubMed -NCBI, 2019.

A. W. Tolcher and L. D. Mayer, Improving combination cancer therapy: the CombiPlex® development platform, Future Oncol Lond Engl, vol.14, issue.13, pp.1317-1349, 2018.

C. Brunetti, L. Anelli, A. Zagaria, G. Specchia, and F. Albano, CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?, Expert Rev Hematol, vol.10, issue.10, pp.853-62, 2017.

M. Kim and S. Williams, Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes, Ann Pharmacother, vol.52, issue.8, pp.792-800, 2018.

, Preparation & Administration | VYXEOS® (daunorubicin and cytarabine

, European Medicines Agency, 2018.

, VYXEOS® Mechanism of Delivery -Secondary AML Treatment | VYXEOS® (daunorubicin and cytarabine) HCP [Internet, 2020.

L. Bernard, T. Eljezi, H. Clauson, C. Lambert, Y. Bouattour et al., Effects of flow rate on the migration of different plasticizers from PVC infusion medical devices, PloS One, vol.13, issue.2, p.192369, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01781597

, Référence 146706 -Concentrateur 5000 Daltons Vivaspin 6 -Dominique DUTSCHER -Matériel de laboratoire

E. B. Manaia, M. P. Abuçafy, B. G. Chiari-andréo, B. L. Silva, O. Junior et al., Physicochemical characterization of drug nanocarriers, Int J Nanomedicine, vol.12, pp.4991-5011, 2017.

M. Donnette, C. Solas, M. Giocanti, G. Venton, L. Farnault et al., Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients, J Chromatogr B Analyt Technol Biomed Life Sci, pp.1126-1127, 2019.

A. Dicko, S. Kwak, A. A. Frazier, L. D. Mayer, and B. D. Liboiron, Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin, Int J Pharm, vol.391, issue.1-2, pp.248-59, 2010.

G. Sicard, G. Venton, L. Farnault, R. Costello, R. Fanciullino et al., Mise en place d'un outil d'aide à la détection des interactions physico-chimiques en Y des médicaments injectables : analyse rétrospective des prescriptions dans un service d'hématologie. Pharm Hosp Clin, vol.54, pp.348-55, 2019.

P. Chan, K. Heatherly, T. C. Kupiec, and L. A. Trissel, Compatibility of caspofungin acetate injection with other drugs simulated y-site coadministration, Int J Pharm Compd, vol.12, issue.3, pp.276-284, 2008.

, King Guide IV Drug Compatibility Wall Charts, 2019.

, Physicochemical characterization of drug nanocarriers. -PubMed -NCBI, 2019.

G. J. Peters, R. J. Honeywell, M. Maulandi, E. Giovannetti, N. Losekoot et al., Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment, Nucleosides Nucleotides Nucleic Acids, vol.33, pp.403-415, 2014.

T. L. Lin, L. F. Newell, R. K. Stuart, L. C. Michaelis, E. Rubenstein et al., A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias, Cancer Chemother Pharmacol, vol.84, issue.1, pp.163-73, 2019.

S. Faderl, J. E. Cortes, E. K. Ritchie, R. J. Ryan, M. Chiarella et al., Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study, Clin Lymphoma Myeloma Leuk, vol.19, pp.206-213, 2019.